Zimeldine

Summary

Zimeldine (CHEMBL37744) is an approved small molecule (ATC N06AB02); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AB02
• Indications: 1 condition
• Chemistry: 317.22 Da · C16H17BrN2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL37744
Name	Zimeldine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5365247
ATC	N06AB02
Molecular formula	C16H17BrN2
Molecular weight	317.22
InChIKey	OYPPVKRFBIWMSX-SXGWCWSVSA-N

SMILES: CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2

IUPAC name: (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine

Also known as: Cis-zimelidine, Normud, Zimeldina, Zimeldine, Zimelidine, Zelmid, zimelidine, SID90340829, SID50104953, zimeldine, ZIMELDINE

Parent form; salt/anhydrous children: CHEMBL1257002, CHEMBL1257115, CHEMBL2355333

Patent coverage: 1,395 distinct patent families (5,465 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,458 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Alpha-2A adrenergic receptor, Neuronal acetylcholine receptor subunit alpha-4, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2C, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Histamine H1 receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA2B	6.85	AC50	140	nM	CHEMBL_ACT_25143182
SLC6A4	6.5	AC50	320	nM	CHEMBL_ACT_25149823
ADRA2C	6.21	AC50	620	nM	CHEMBL_ACT_25147345
KCNH2	6.19	AC50	650	nM	CHEMBL_ACT_25117075
HTR2C	5.8	AC50	1600	nM	CHEMBL_ACT_25131290
OPRM1	5.51	AC50	3100	nM	CHEMBL_ACT_25146633
P31652	5.35	IC50	4500	nM	CHEMBL_ACT_1270452
P31652	5.21	IC50	6100	nM	CHEMBL_ACT_131696
ADRA2A	5.01	AC50	9800	nM	CHEMBL_ACT_25219397

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).